Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: Targeted drugs; Drug: PD-1 monoclonal antibody Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials